Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema
Status:
Withdrawn
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety of intravitreal ranibizumab repeated injections in patients with
diabetic macular edema regarding maintenance of retinal ganglion cell function.